Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 17-28

  Rahoma, S F E ^a   Sandhu, H K ^a   McDonagh, A J G ^b   Gawkrodger, D J ^b   Weetman, A P ^a   Kemp, E Helen ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; DNA FRAGMENT; ENZYME ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; TYROSINE 3 MONOOXYGENASE; TYROSINE HYDROXYLASE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; SCHOOL CHILD; VITILIGO;

ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; AUTOANTIBODIES; BINDING SITES; CHILD; CHILD, PRESCHOOL; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; TYROSINE 3-MONOOXYGENASE; VITILIGO; YOUNG ADULT;

EID: 84863303010     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10889.x     Document Type: Article

References (43)

1. Taieb A, Picardo M, Vitiligo European Task Force (VETF) Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20:27-35. (Pubitemid 46090162)
2. Shapiro J, Madani S. Alopecia areata: diagnosis and management. Int J Dermatol 1999; 38 (Suppl. 1):S19-24.
3. Tobin DJ. Morphological analysis of hair follicles in alopecia areata. Microsc Res Tech 1997; 38:443-51. (Pubitemid 27377656)
4. Safavi KH, Muller SA, Suman VJ et al. Incidence of alopecia areata in Olmsted County, Minnesota 1975-1989. Mayo Clin Proc 1995; 70:628-33.
5. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993; 129:994-8. (Pubitemid 23238604)
6. Schmidt S, Fischer TW, Chren MM et al. Strategies of coping and quality of life in women with alopecia. Br J Dermatol 2001; 144:1038-43.
7. Linthorst Homan MW, Spuls PI, de Korte J et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61:411-20.
8. Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genomics 2011; 38:271-8. (Pubitemid 47057312)
9. Alkhateeb A, Fain PR, Thody A et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their relatives. Pigment Cell Res 2003; 16:208-14. (Pubitemid 36597056)
10. Petukhova L, Duvic M, Hordinsky M et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466:113-17.
11. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006; 20:1055-60. (Pubitemid 44425959)
12. Kalish RS, Johnson KL, Hordinsky MK. Alopecia areata: autoreactive T cells are variably enriched in scalp lesions relative to peripheral blood. Arch Dermatol 1992; 128:1072-7.
13. Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 2005; 5:64-9. (Pubitemid 41759444)
14. Kang H, Wu WY, Lo BK et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J Invest Dermatol 2010; 130:2677-80.
15. van den Boorn JG, Konijnenberg D, Dellemijn TAM et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129:2220-32.
16. Norris DA, Kissinger RM, Naughton GK, Bystryn J-C. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90:783-9.
17. Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105:683-6.
18. Harning R, Cui J, Bystryn J-C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97:1078-80.
19. 35S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997; 109:69-73.
20. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998; 114:333-8. (Pubitemid 28539590)
21. Li Q, Lv Y, Li C et al. Vitiligo autoantigen VIT75 is identified as lamin A in vitiligo by serological proteome analysis based on mass spectrometry. J Invest Dermatol 2010; 131:727-34.
22. Kemp EH, Waterman EA, Hawes BE et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109:923-30. (Pubitemid 34275113)
23. Gilhar A, Pillar T, Assy B, David M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br J Dermatol 1992; 126:166-71.
24. Tobin DJ. Characterisation of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc 2003; 8:176-81. (Pubitemid 37222826)
25. Tobin DJ, Bystryn JC. Alopecia areata is associated with antibodies to hair follicle-specific antigens located predominantly in the proliferative region of hair follicles. In: Hair Research for the Next Millennium (Neste JJ, Randall VA, eds). Amsterdam: Elsevier Science, 1996; 237-41.
26. Leung MC, Sutton CW et al. Trichohyalin is a potential major autoantigen in human alopecia areata. J Proteome Res 2010; 9:5153-63.
27. Galbraith GMP, Miller D, Emerson DL. Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. Clin Immunol Immunopathol 1988; 48:317-24.
28. Kemp EH, Emhemed S, Akhtar S et al. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol 2011; 20:35-40.
29. Kemp EH, Sandhu HK, Weetman AP, McDonagh AJ. Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata. Br J Dermatol 2011; 161:1236-43.
30. Kemp EH, Waterman EA, Gawkrodger DJ et al. Identification of epitopes on tyrosinase which are recognised by autoantibodies from patients with vitiligo. J Invest Dermatol 1999; 113:267-71. (Pubitemid 30202534)
31. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
32. Kemp EH, Waterman EA, Gawkrodger DJ et al. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998; 139:798-805. (Pubitemid 28520285)
33. Cucnik S, Kveder T, Ulcova GZ et al. The avidity of anti-β2- glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus 2011; 20:1166-71.
34. Ekwall O, Hedstrand H, Haavik J et al. Pteridin-dependent hydroxylases as autoantigens in autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2000; 85:2944-50. (Pubitemid 32269178)
35. Zanelli E, Henry M, Malthiery Y. Use of recombinant epitopes to study the heterogeneous nature of the autoantibodies against thyroid peroxidase in autoimmune thyroid disease. Clin Exp Immunol 1992; 87:80-6.
36. Lampasona V, Bearzatto M, Genovese S et al. Autoantibodies in insulin-dependent diabetes recognise distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 1996; 157:2707-11. (Pubitemid 126450489)
37. Naserke HE, Ziegler AG, Lampasona V, Bonafacio E. Early development and speading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998; 161:6963-9. (Pubitemid 28562244)
38. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001; 108:1097-104. (Pubitemid 32995366)
39. Petterson I. Methods of epitope mapping. Mol Biol Rep 1992; 16:149-53.
40. Morgenthaler NG, Hodak K, Seissler J et al. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay. Thyroid 1999; 9:467-75. (Pubitemid 29244924)
41. Syren K, Lindsay L, Stoehrer B et al. Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J Immunol 1996; 157:5208-14. (Pubitemid 126449606)
42. Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ et al. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83:683-95. (Pubitemid 36618047)
43. Hedstrand H, Ekwall O, Haarvik J et al. Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type 1. Biochem Biophys Res Commun 2000; 267:456-61. (Pubitemid 30072573)